{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:30:43Z","timestamp":1786735843138,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Niger J Clin Pract"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/njcp.njcp_587_18","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T06:37:36Z","timestamp":1562740656000},"page":"997","source":"Crossref","is-referenced-by-count":3,"title":["The postoperat\u0131ve effects of use of trimetazidine before the coronary artery bypass graft surgery"],"prefix":"10.4103","volume":"22","author":[{"given":"BE","family":"Golboyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Aksun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Aksun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kestelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Kuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HF","family":"Tanyeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Girgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Damar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Karahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1119-3077.262529-1","first-page":"292","volume-title":"Trimetazidine, a cellular anti- ischemic agent","author":"Harpey","year":"1988","journal-title":"Cardiovasc Drug Rev"},{"key":"key-10.4103\/1119-3077.262529-2","first-page":"143","volume-title":"Trimetazidine.A review of its use in stable angina pectoris and other coronary conditions","author":"McClellan","year":"1999","journal-title":"Drugs"},{"key":"key-10.4103\/1119-3077.262529-3","first-page":"147","volume-title":"Adverse effects of free fatty acid associated with increased oxidative stress in postischemic isolated rat hearts","author":"Gambert","year":"2006","journal-title":"Mol Cell Biochem"},{"key":"key-10.4103\/1119-3077.262529-4","first-page":"580","volume-title":"The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase","author":"Kantor","year":"2000","journal-title":"Circ Res"},{"key":"key-10.4103\/1119-3077.262529-5","doi-asserted-by":"crossref","unstructured":"Adams JE 3rd, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s?. Circulation 1993;88:750-63.","DOI":"10.1161\/01.CIR.88.2.750"},{"key":"key-10.4103\/1119-3077.262529-6","first-page":"332","volume-title":"Twelve-year follow-up of survival in the randomized European coronary surgery study","author":"Varnauskas","year":"1988","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1119-3077.262529-7","first-page":"391","volume-title":"Reperfusion injury: Etiology, mechanisms, and herapies","author":"Hoffman","year":"2004","journal-title":"J Extra Corpor Technol"},{"key":"key-10.4103\/1119-3077.262529-8","first-page":"242","volume-title":"Relation between left ventricular function and oxidative stress in patients undergoing bypass surgery","author":"De","year":"1998","journal-title":"Heart"},{"key":"key-10.4103\/1119-3077.262529-9","first-page":"86","volume-title":"The effectiveness of preoperative trimetazidine on myocardial preservation in coronary artery bypass graft patients: A systematic review and meta-analysis","author":"ZhangN,","year":"2015","journal-title":"Cardiology"},{"key":"key-10.4103\/1119-3077.262529-10","first-page":"e33","volume-title":"Beneficial effects of trimetazidine in ex vivo working ischemichearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase","author":"Lopaschuk","year":"2003","journal-title":"Circ Res"},{"key":"key-10.4103\/1119-3077.262529-11","first-page":"971","volume-title":"Defining the role of trimetazidine in the treatment of cardiovascular disorders: Some insights on its role in heart failure and peripheral artery disease","author":"Chrusciel","year":"2014","journal-title":"Drugs"},{"key":"key-10.4103\/1119-3077.262529-12","first-page":"2173","volume-title":"Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting","author":"T\u00fcnerir","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"key-10.4103\/1119-3077.262529-13","first-page":"175","volume-title":"Trimetazidine may protect the myocardium during cardiac surgery","author":"Iskesen","year":"2009","journal-title":"Heart Surg Forum"},{"key":"key-10.4103\/1119-3077.262529-14","first-page":"29","volume-title":"The cardioprotective effects of trimetazidine during off-pump coronary artery bypass grafting","author":"Xu","year":"2014","journal-title":"Henan Med Res"},{"key":"key-10.4103\/1119-3077.262529-15","first-page":"017","volume-title":"The cardioprotective efficacy of TMZ during coronary artery bypass graft surgery","author":"Wang","year":"2003","journal-title":"Chin J Med Guide"},{"key":"key-10.4103\/1119-3077.262529-16","first-page":"58","volume-title":"Diabetes and cardiovascular disease: Changing the focus from glycemic control to improving long-term survival","author":"Wang","year":"2012","journal-title":"Am J Cardiol"},{"key":"key-10.4103\/1119-3077.262529-17","first-page":"697240","volume-title":"Diabetes and coronary heart disease: A risk factor for the global epidemic","author":"Chiha","year":"2012","journal-title":"Int J Hypertens"},{"key":"key-10.4103\/1119-3077.262529-18","first-page":"611","volume-title":"Effects of trimetazidineon myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy","author":"Belardinelli","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"key":"key-10.4103\/1119-3077.262529-19","first-page":"16","volume-title":"Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: A double blind placebo controlled study","author":"Rosano","year":"2003","journal-title":"Cardiovasc Diabetol"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:34:14Z","timestamp":1786732454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_587_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"alternative-id":["262529"],"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_587_18","relation":{},"ISSN":["1119-3077"],"issn-type":[{"value":"1119-3077","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}